Clarification of action mechanism of Halaven (Eribulin) using MRI

Clarification of action mechanism of Halaven (Eribulin) using MRI - Clarification of action mechanism of Halaven using MRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027331

Enrollment

Registered

2017-05-15

Start date

2017-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced or metastatic breast cancer patients who are to be treated with Halaven at Tokai University Hospital 2. Patients with measurable lesions by contrast-enhanced MRI; lymph node metastasis, liver metastasis, or osteolytic bone metastasis with shortest dimension larger than 2cm. 3. Patients who can hold breath for 20 seconds and can follow instruction during MR examinations. 4. Patients who give written informed consent for this study.

Exclusion criteria

Exclusion criteria: 1.Patients with concomitant radiation therapy for the target lesions. 2.Allergy to Gd-contrast. 3.Patients with asthma 4.Patients with renal dysfunction 5.Pregnant or breast feeding 6.Implanted metallic or electronic device not confirmed safety at 3T-MRI. 7.Patients with difficult venous access.

Design outcomes

Primary

Measure	Time frame
Perfusion of tumor before, 8 days-, 29 days-, 90 days- after start of Halaven treatment	—

Secondary

Measure	Time frame
ADC and size of tumor before, 8 days-, 29 days-, 90 days- after start of Halaven treatment	—

Countries

Japan

Contacts

Public ContactToshiki Kazama

Tokai University Hospital Department of Diagnostic Radiology

kazamat@fg7.so-net.ne.jp0463-93-1121

Outcome results